Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 5, 2011, Pages 543-549

  Ogawa, Kiyohiro ^a   Hirooka, Yoshitaka ^a   Kishi, Takuya ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

angiotensin II; brain inflammation; heart failure; toll like receptor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MYELOID DIFFERENTIATION FACTOR 88; NORADRENALIN; TOLL LIKE RECEPTOR 4; MYD88 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BRAIN STEM; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; LEFT CORONARY ARTERY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; NORADRENALIN URINE LEVEL; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN BINDING; SHAM PROCEDURE; TREATMENT DURATION; ANIMAL; BIOLOGICAL MODEL; BODY WEIGHT; BRAIN; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART; HEART LEFT VENTRICLE FUNCTION; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ANGIOTENSIN II; ANIMALS; BODY WEIGHT; BRAIN; BRAIN STEM; ELECTROCARDIOGRAPHY; HEART; HEART FAILURE; INFUSIONS, INTRAVENTRICULAR; LOSARTAN; MALE; MICE; MICE, INBRED ICR; MODELS, BIOLOGICAL; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; NF-KAPPA B; NOREPINEPHRINE; ORGAN SIZE; RECEPTOR, ANGIOTENSIN, TYPE 1; SYMPATHETIC NERVOUS SYSTEM; TOLL-LIKE RECEPTOR 4; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80955142869     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822e6b40     Document Type: Article

References (45)

1. Meredith IT, Eisenhofer G, Lambert GW, et al. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation. 1993;88:136-145.
2. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J. 1989; 118:642-648.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992; 20:248-254.
4. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
5. Goldsmith SR. Angiotensin II and sympathoactivation in heart failure. J Cardiac Fail. 1999;5:139-145.
6. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res. 1999;84:417-423.
7. Gao L, Wang W, Li YL, et al. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res. 2004;95:937-944.
8. Murakami H, Liu JL, Zucker IH. Angiotensin II blockade [corrected] enhances baroreflex control of sympathetic outflow in heart failure. Hypertension. 1997;29:564-569.
9. Lindley TE, Doobay MF, Sharma RV, et al. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res. 2004;94:402-409.
10. Liu D, Gao L, Roy SK, et al. Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circ Res. 2006;99:1004-1011.
11. Ahmad M, White R, Tan J, et al. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction. J Cardiovasc Pharmacol. 2008;51:565-572.
12. Zucker IH, Schultz HD, Patel KP, et al. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol. 2009;297:H1557-H1566.
13. Kimura Y, Hirooka Y, Kishi T, et al. Role of inducible nitric oxide synthase in rostral ventrolateral medulla in blood pressure regulation in spontaneously hypertensive rats. Clin Exp Hypertens. 2009;31:281-286.
14. Yu Y, Zhang ZH, Wei SG, et al. Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension. 2010;55:652-659.
15. Marvar PJ, Thabet SR, Guzik TJ, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 2010;107:263-270.
16. Kimura Y, Hirooka Y, Sagara Y, et al. Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res. 2005;96: 252-260.
17. Zhang ZH, Yu Y,Wei SG, et al. Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogenactivated protein kinase signaling. J Hypertens. 2010;28:806-816.
18. Kishi T, Hirooka Y, Konno S, et al. Angiotensin II type 1 receptoractivated caspase-3 through ras/mitogen-activated protein kinase/ extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension. 2010;55:291-297.
19. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev. 2004;4: 499-511.
20. Caso JR, Pradillo JM, Hurtado O, et al. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007;115:1599-1608.
21. Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, et al. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci. 2010;30:8285-8295.
22. Gorina R, Font-Nieves M, Marquez-Kisinousky L, et al. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkB signaling, MAPK, and Jak1/Stat1 pathways. Glia. 2011;59:242-255.
23. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003;100:8514-8519.
24. Wolf G, Bohlender J, Bondeva T, et al. Angiotensin II upregulates tolllike receptor 4 on mesangial cells. J Am Soc Nephrol. 2006;17: 1585-1593.
25. Wu J, Yang X, Zhang YF, et al. Angiotensin II upregulates toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm Res. 2009;58:473-482.
26. Lazartigues E, Sinnayah P, Augoyard G, et al. Enhanced water and salt intake in transgenic mice with brain-restricted overexpression of angiotensin (AT1) receptors. Am J Physiol. 2008;295:R1539-R1545.
27. Kishi T, Hirooka Y, Sakai K, et al. Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension. 2001;38:896-901.
28. Kishi T, Hirooka Y, Ito K, et al. Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;39: 264-268.
29. Kishi T, Hirooka Y, Kimura Y, et al. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation. 2004;109:3257-3262.
30. Zimmerman MC, Lazartigues E, Sharma RV, et al. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210-216.
31. Yang J, Jiang H, Yang J, et al. Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kB signalling pathway. Mol Cell Biochem. 2009;330:39-46.
32. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis. 2009;202:76-83.
33. Lv J, Jia R, Yang D, et al. Candesartan attenuates angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun. 2009;380:81-86.
34. Cheng XW, Song H, Sasaki T, et al. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension. 2011;57:981-989.
35. Hirooka Y, Kishi T, Sakai K, et al. Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am J Physiol. 2011;300: R818-R826.
36. Van Tassell BW, Seropian IM, Toldo S, et al. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol. 2010;55:385-390.
37. Dampney RAL. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994;74:323-364.
38. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346.
39. McKinley MJ, Albinson AL, Allen AM, et al. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol. 2003;35: 901-918.
40. Dupont AG, Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens. 2010;28:1599-1610.
41. Allen AM, O'Callaghan EL, Chen D, et al. Central neural regulation of cardiovascular function by angiotensin: a focus on the rostral ventrolateral medulla. Neuroendocrinology. 2009;89:361-369.
42. Wang E, Feng Y, Zhang M, et al. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms. Anesthesiology. 2011;114:603-613.
43. Riad A, Jäger S, Sobirey M, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 2008;180:6954-6961.
44. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
45. Lin L, Kim SC, Wang Y, et al. HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis. Am J Physiol. 2007;293: H2238-H2247.